270 related articles for article (PubMed ID: 16465153)
1. A turbulent year at the agency.
Ratner M
Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
[No Abstract] [Full Text] [Related]
2. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
3. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
4. FDA appointee faces angry, demoralized staff.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
[No Abstract] [Full Text] [Related]
5. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
6. New office and new leader aim to streamline FDA cancer drug review process.
Twombly R
J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
[No Abstract] [Full Text] [Related]
7. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
8. Regulators scramble to tighten loopholes after heparin debacle.
Jia H
Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
[No Abstract] [Full Text] [Related]
9. Congress turns spotlight on US drug approval agency.
Gavaghan H
Nature; 1995 Apr; 374(6523):582. PubMed ID: 7715685
[No Abstract] [Full Text] [Related]
10. An overview from the Director of the Center for Food Safety and Applied Nutrition.
Levitt JA
Food Drug Law J; 1999; 54(1):43-48. PubMed ID: 11758559
[No Abstract] [Full Text] [Related]
11. Sweeping changes to Food and Drug Administration and drug safety regulations.
Cross JT
Arch Intern Med; 2007 Apr; 167(7):732. PubMed ID: 17420439
[No Abstract] [Full Text] [Related]
12. The safety of medical devices and the role of the FDA.
Pillar B
Nurs Econ; 1991; 9(4):284-6. PubMed ID: 1922433
[No Abstract] [Full Text] [Related]
13. Legal overprotection.
Friedman JH
Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
[No Abstract] [Full Text] [Related]
14. Dynavax trial halted.
DeFrancesco L
Nat Biotechnol; 2008 May; 26(5):484. PubMed ID: 18464766
[No Abstract] [Full Text] [Related]
15. FDA plan for statutory compliance. Notice of availability.
Fed Regist; 1998 Nov; 63(226):65000-40. PubMed ID: 10338873
[TBL] [Abstract][Full Text] [Related]
16. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
17. FDA restructures new product review centers.
Bouchie A
Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
[No Abstract] [Full Text] [Related]
18. Is the FDA on drugs?
Calabresi M; Park A
Time; 2010 Aug; 176(8):24-8. PubMed ID: 20821962
[No Abstract] [Full Text] [Related]
19. Is the Food and Drug Administration safe and effective?
Philipson TJ; Sun E
J Econ Perspect; 2008; 22(1):85-102. PubMed ID: 19728421
[No Abstract] [Full Text] [Related]
20. Drug review "behind the curtain": a response to Professor Struve.
O'Reilly JT
Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
